Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors

Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors

Abstract Immune checkpoint inhibitors (ICIs) have been approved for monotherapy and combined therapy with chemotherapy and/or radiotherapy in China since 2018. The number of patients receiving ICIs has significantly increased in recent years, and the collection and analysis of this data are crucial...

Full description

Saved in:
Bibliographic Details
Main Authors: Qi Zhang, Jialing Chen, Nana Tsai, Xuejuan Zhu, Minyan Zhao, Lirong Meng, Pedro Fong
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Scientific Reports
Subjects:
Immunotherapy
Immune checkpoint inhibitors
Immune-related adverse events
PD-1
PD-L1
Online Access:https://doi.org/10.1038/s41598-024-82105-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items